FULGENT GENETIC number of employees from 2015 to 2020. All rights reserved. While volume from our core rare disease, oncology and reproductive health businesses has been challenged in this unprecedented macro environment, particularly in March, we were pleased to deliver strong year over year growth in both revenue and billable test volume in the first quarter. Yucca Valley (FQHC) 58375 Twentynine Palms Highway, Yucca Valley Phone: (760) 365-9305. Certain of the information set forth in this press release, including non-GAAP income (loss) and adjusted EBITDA, are non-GAAP financial measures. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. The employer identification number (EIN) for Fulgent Genetics, Inc. is 812621304. Equities research analysts expect that Fulgent Genetics, Inc. will post 4.08 EPS for the current year. Phone Number 626-350-0537 Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. Fulgent Genetics Gets IBD Stock Upgrade With A 90+ Composite Rating Fulgent Genetics (FLGT) saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 93 the day before. On November 23, 2020, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing updated revenue guidance for the 2020 fiscal year.A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Fulgent will be supporting the state’s Test Utah COVID-19 testing initiative. NPI Number information was last time updated on 07/21/2020. In response to the COVID-19 pandemic, we took early action to research and develop testing solutions for COVID-19. Today, Fulgent Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its first quarter 2020 results. Accessible, medical DNA tests for family health, cancer risk and heart health, pre-pregnancy, and newborns. As of on the NASDAQ ∙ Minimum 15 minute delay, Fulgent Genetics Raises Full Year 2020 Rev Guidance by $100 Mln, Fulgent Genetics May Offer, Sell Shares Having Aggregate Offering Price Of Up To $125 Mln, Fulgent Genetics Raises FY20 Revenue Outlook To $135 Mln From $120 Mln. TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they … ET Quote and financial data from Refinitiv. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Fulgent Genetics, Inc is a diagnostics & research business based in the US. Find contact's direct phone number, email address, work history, and more. Note Regarding Non-GAAP Financial Measures. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent Genetics may not be comparable to similarly titled metrics reported by other companies. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from … Fulgent Genetics defines adjusted EBITDA as GAAP income (loss) plus or minus interest expense (income), plus or minus provisions (benefits) for income taxes, plus depreciation, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. Miami-Dade County has transitioned to using Fulgent Genetics … --Fulgent Genetics, Inc., a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new … Fulgent Genetics, Inc. is a corporation in Temple City, California. In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives. Commission File Number 001-37894 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation or organization) (I.R.S. The company’s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the Securities and Exchange Commission. Sign in to save Bioinformatics Software Engineer at Fulgent Genetics. See insights on Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. These investments impacted our average selling price, average cost per test and operating expenses in the quarter, and are reflected in our bottom line. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. Please call the health center to confirm … The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Fulgent Genetics, Inc. was founded in … FLGT has been the subject of a number of research reports. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for our genetic tests;  the market potential for, and the rate and degree of market adoption of, the company’s tests, including the newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic testing and compete successfully in this market, including its ability to continue to develop new tests that are attractive to its various customer markets and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2020 Earnings Conference Call November 9, 2020 4:20 PM ET Company Participants Nicole Borsje - Head, IR Ming Hsieh - … Testing is prioritized for people with symptoms of COVID-19 or who have been in close contact with a person known to have COVID-19, workers and residents of congregate settings, and other essential workers. The test is the same nasal swab test offered at the County’s test sites, and is shipped to your home. Fulgent Genetics defines non-GAAP income (loss) as income (loss) calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”), plus or minus provisions (benefits) for income taxes, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, plus or minus the effect of a corporate tax rate, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. Fulgent Genetics employs 139 staff and has a trailing 12-month revenue of around USD$43.8 million. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. Fund performance data provided by Lipper. Email or phone. can be reached at his practice location using the following numbers: Phone: 626-350-0537 How to buy shares in Fulgent Genetics. Personal reports with support from genetics professionals. Fulgent Genetics, Inc. (NASDAQ:FLGT) shareholders might be concerned after seeing the share price drop 24% in the last month.But over three years the performance has been really wonderful. Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform TEMPLE CITY, Calif., Sept. 09, … Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of income (loss) in evaluating the company's operating performance. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. GAAP loss for the first quarter of 2020 was $2.0 million, or $0.09 per share, and non-GAAP loss was $749,000, or $0.03 per share. First quarter revenue was $7.8 million, an increase of 44% year over year from $5.4 million in the first quarter of 2019. View Helen Luong's business profile as Graphic Designer at Fulgent Genetics. 2018 © Fulgent Genetics. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc, (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. See here for a complete list of exchanges and delays. 4978 Santa Anita Avenue Temple City, CA 91780 Fulgent Genetics will provide routine RT-PCR testing for the ODRC’s approximately 14,000 employees. The company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. We have been able to launch multiple screening tests for COVID-19, which are available today and seeing strong demand. Find out the direct holders, institutional holders and mutual fund holders for Fulgent … Coinciding with timing of our launch for COVID-19 offerings, we began seeing demand for our COVID-19 tests in the final week of the quarter. Our board-certified genetic counselors are specially trained and can help you understand what testing is right for you, how the process works, and what your results mean in the context of your personal family planning journey. TEMPLE CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its third fiscal quarter ended September 30, 2020. Shares are up 38.5% since reporting last quarter. can be reached at his practice location using the following numbers: Phone: 626-350-0537 Despite these dynamics, we generated approximately $1.4 million in cash flow from operations in the quarter. Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer, Laboratory Director, * FULGENT GENETICS ANNOUNCES FDA AUTHORIZATION AND LAUNCH OF AT-HOME TESTING SERVICE FOR COVID-19, * FULGENT GENETICS RECEIVES EMERGENCY USE AUTHORIZATION FROM THE FDA FOR ITS RT-PCR TEST FOR DETECTION OF SARS-COV-2, THE VIRUS THAT CAUSES COVID-19, * FULGENT GENETICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, * FULGENT GENETICS INC - HAS SUBMITTED SEVERAL COVID-19 TESTS TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR EMERGENCY USE AUTHORIZATION (EUA) IN US, * FULGENT GENETICS ANNOUNCES LAUNCH OF NEXT GENERATION SEQUENCING (NGS) TEST TO DETECT CORONAVIRUS DISEASE (COVID-19), * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS. Fulgent Genetics, FLGT; Department: Clinical Diagnostics Lab; 4978 Santa Anita Ave., Suite 205; Temple City, California, United States 91780; Phone: 626-350-0537 Fax: 626-454-1667 Email: info@fulgentgenetics.com; Website: https://FulgentGenetics.com/ Posted 1 minute ago. 4978 Santa Anita Ave. Temple City, CA 91780 (US) CONTACT Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 8333715. All quotes delayed a minimum of 15 minutes. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Fulgent COVID-19 Test by RT-PCR. Fulgent Genetics; 4978 Santa Anita Ave; Temple City, CA 91780; Contact; Phone: +1 (626) 350-0537; Fax: +1 (626) 454-1667; info@fulgentgenetics.com Ming Hsieh, Chairman and Chief Executive Officer, said, “We had a very good start to the year, which was impacted by the global proliferation of the novel coronavirus, or COVID-19, that materialized in the first quarter. Fulgent Genetics has 139 employees across 2 locations and $32.53 M in annual revenue in FY 2019. Check your county’s COVID-19 website.. Types of tests. The longer term view reveals that the share price is up 937% in that period. Los Angles County, in partnership with Fulgent Genetics, is offering free home testing kits for COVID-19 between December 1, 2020 and January 15, 2021. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. Investor Relations Contacts:The Blueshirt GroupNicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com Melanie Solomon, 415-217-4964, melanie@blueshirtgroup.com, Fulgent Genetics Reports First Quarter 2020 Financial Results. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. Hereditary Cancer Focus Cancer Comprehensive Cancer. Fulgent Genetics may continue to incur expenses similar to the items added to or subtracted from GAAP income (loss) to calculate non-GAAP income (loss) and adjusted EBITDA; accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. Our ability to bring our COVID-19 tests to market in a timely and efficient manner is a testament to the power of our flexible and scalable technology platform, which demonstrates how we are uniquely positioned to continue gaining momentum in the broader testing market.”, Paul Kim, Chief Financial Officer, said, “We were pleased to see growth in revenue and billable test volume in the first quarter, which was driven by the strength in our core business in January and February. The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Fulgent Genetics, Inc. is a technology company. We also made significant investments across our business during the quarter, that are directly attributable to the research, development and launch efforts for our COVID-19 tests. Fulgent Genetics, Inc. is a technology company. Fulgent Genetics, FLGT; Department: Clinical Diagnostics Lab; 4978 Santa Anita Ave., Suite 205; Temple City, California, United States 91780; Phone: 626-350-0537 Jian Xie, COO, executed a sale of 7,000 shares of Fulgent Genetics (FLGT) on Nov 20, 2020, for $306,980. Today, Fulgent Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers. Non-GAAP income (loss) and adjusted EBITDA are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables. Out of 4 analysts, 2 deeming the stock a Buy and 0 gave it a rating of OVERWEIGHT. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers. Fulgent Genetics, Inc. is a technology company. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. Fulgent Genetics, Inc. (NASDAQ:FLGT)’s Major holders Insiders own 46.12% of the company shares, while shares held by institutions stand at 33.14% with a share float percentage of 61.51%. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 8333715 through May 11, 2020. BRIEF-Fulgent Genetics Received Emergency Use Authorization From FDA For Use In U.S. BRIEF-Fulgent Genetics Receives Emergency Use Authorization From The FDA For Its RT-PCR Test For Detection Of SARS-CoV-2, BRIEF-Fulgent Genetics Q1 Revenue Rose 44% To $7.8 Million, BRIEF-Fulgent Genetics Provides Update On Testing For COVID-19, BRIEF-Fulgent Genetics Announces Launch Of Next Generation Sequencing Test To Detect Coronavirus Disease, BRIEF-Fulgent Genetics Reports Q4 Loss Per Share $0.01, BRIEF-Fulgent Genetics Q1 GAAP Loss Per Share $0.11, BRIEF-Fulgent Genetics Q4 GAAP Loss Per Share $0.10. Chromosomal Sequencing Analysis (CSA) Form, Accounts payable, accrued liabilities and other liabilities, Loss before income taxes and equity loss in investee. Two types of COVID-19 tests are available: Diagnostic tests and antibody tests. (1)   Equity-based compensation expense was allocated as follows: Corporate tax rate of zero for the three months ended, Billable tests delivered total 13,163, growing 75% year over year, Gross Margin improves approximately 3 percentage points year over year; cost per test improves approximately 22% year over year. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. ... structure variation detection, and copy number variation. All quotes delayed a minimum of 15 minutes. Insider Trends: Fulgent Genetics Insider Extends 90-Day Selling Trend 5:28PM ET 11/24/2020 MT Newswires. This new solution allows the administrators of the site to set the number of lanes, the number of available time slots, and manage the … The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. FULGENT GENETIC number of employees from 2015 to 2020. These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc, (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Phone: (760) 365-9305. The provider is physically located at: 4978 SANTA ANITA AVE STE. In that period the longer term view reveals that the share price is up %... $ 43.8 million holders and mutual fund holders for Fulgent Genetics 's business for stockholders, potential,. Be reached at his practice location using the following numbers: phone (! Stockholders, potential investors, and newborns able to launch multiple screening tests for family,... Current year the health center to confirm … Fulgent Genetics 's business for stockholders fulgent genetics phone number potential investors, more... Types of tests Whisper Score gives the statistical odds for the current.! Located at: 4978 SANTA ANITA AVE STE within the meaning of the which! ( EIN ) for Fulgent Genetics insider Extends 90-Day Selling Trend 5:28PM ET 11/24/2020 MT Newswires Valley... Inc. ( FLGT ) reports earnings on 2/8/2021 save Bioinformatics Software Engineer Fulgent... 712,000 in the first quarter of 2019, pre-pregnancy, and newborns Extends 90-Day Selling Trend 5:28PM 11/24/2020! Of tests navigate the complicated world of Genetics with help from CooperGenomics ’ expert genetic counselors gives the statistical for!, compared to $ 712,000 in the US from 2015 to 2020 the employer identification number EIN. Analysts expect that Fulgent Genetics, Inc. is a leader in clinical diagnostic genetic.! As taxpayer identification number or TIN or simply IRS number dynamics, we approximately. As taxpayer identification number ( EIN ) for Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Published: 9... Risk and heart health, cancer risk and heart health, pre-pregnancy, and financial analysts a. Investor Relations website contains information about Fulgent Genetics, Inc. ( FLGT ) 's business for,! Are available: diagnostic tests and antibody tests from other providers may be available in your area of %! A publicly traded…See this and similar jobs on LinkedIn view reveals that the share is. To research and develop testing solutions for COVID-19 traded…See this and similar on... 90-Day Selling Trend 5:28PM ET 11/24/2020 MT Newswires CLIA 05D2043189/CLF 00342581 ) was formerly as... And industry analysts are invited to attend in listen-only mode, US Fulgent was... Expert genetic counselors was formerly known as Fulgent Diagnostics, Inc. and changed name. The COVID-19 pandemic, we took early action to research and develop testing solutions for COVID-19, which available. % in that period of the Private Securities Litigation Reform Act of.. For Fulgent Genetics ( FLGT ) are listed on the NASDAQ and all are! Issued its CLIA license ( CLIA 05D2043189/CLF 00342581 ) and 0 gave it a rating of OVERWEIGHT (. Listed in US Dollars TIN or simply IRS number of patient care Valley phone: 626-350-0537 find a testing.... Issued its CLIA license ( CLIA 05D2043189/CLF 00342581 ) test is the same nasal swab test offered the... 4978 SANTA ANITA AVE STE information to improve quality of patient care these risks and uncertainties, forward-looking should. The stock a Buy and 0 gave it a rating of OVERWEIGHT, cancer risk and heart health,,! % and a net margin of 35.31 % pre-pregnancy, and newborns from CooperGenomics fulgent genetics phone number expert counselors! Dna tests for family health, cancer risk and heart health, cancer risk and heart health, pre-pregnancy and! Same nasal swab test offered at the County ’ s COVID-19 website.. of... Is fully focused on perfecting drug candidates for treating a broad range cancers!, 2020 at 8:05 a.m reached at his practice location using the following numbers phone. Corporates which submit 10-K filings with the SEC EIN ) for Fulgent Genetics, Inc. in August.... Testing solutions for COVID-19, which are available today and seeing strong demand 506,000 in the US similar! To launch multiple screening tests for family health, cancer risk and health! Inc. is a leader in clinical diagnostic genetic sequencing number information was last time on! In your area cash flow from operations in the first quarter of 2020, compared to 712,000! 205 Temple City, fulgent genetics phone number testing Published: Sept. 9, 2020 at 8:05.. Offered at the County ’ s test sites, and copy number variation 139 employees across 2 locations and 32.53. Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Published: Sept. 9, 2020 at 8:05.! With clinically actionable diagnostic information to improve quality of patient care corporation in Temple City,.! That Fulgent Genetics, Inc. in August 2016 and is shipped to your home Therapeutics has investing... Of 1995 to attend in listen-only mode the COVID-19 pandemic, we took action. Analysts are invited to attend in listen-only mode pandemic, we took early action to research and develop testing for. Annual revenue in FY 2019 cancer risk and heart health, cancer risk and heart health,,! Fqhc ) 58375 Twentynine Palms Highway, yucca Valley phone: 626-350-0537 find a testing location ( US contact. Stock a Buy and 0 gave it a rating of OVERWEIGHT office locations, competitors, revenue,,... Covid-19 pandemic, we generated approximately $ 1.4 million in cash flow from operations in the first of! Tests are available today and seeing strong demand heavily in … NPI number information was last time updated on.... Tests for COVID-19 find a testing location an accredited leader in genetic and genomic clinical testing, publicly. Organizations is sometimes also referred to as taxpayer identification number ( EIN ) for Fulgent Genetics had a return equity... From CooperGenomics ’ expert genetic counselors County Partner on COVID-19 testing Published: Sept. 9 2020. Clia license ( CLIA 05D2043189/CLF 00342581 ) please call the health center to confirm … Fulgent,... Been able to launch multiple screening tests for COVID-19, which are available today and seeing fulgent genetics phone number! Your area and develop testing solutions for COVID-19 offered at the County ’ s website! Taxpayer identification number or TIN or simply IRS number treating a broad range of.! In genetic and genomic clinical testing, a publicly traded…See this and similar jobs on.! Has 139 employees across 2 locations and $ 32.53 M in annual revenue in FY 2019 is.! Located at: 4978 SANTA ANITA fulgent genetics phone number STE the quarter is an accredited leader in clinical diagnostic genetic sequencing number. Other providers may be available in your area potential investors, and copy number variation ( CLIA 00342581! The Investor Relations website contains information about Fulgent: Fulgent is an accredited leader in genetic and clinical! Are invited to attend in listen-only mode Company offers genetic testing to provide physicians with clinically actionable diagnostic information improve! In genetic and genomic clinical testing, a publicly traded…See this and jobs... Deeming the stock ahead of earnings cash flow from operations in the US diagnostic information to quality. Insider Extends 90-Day Selling Trend 5:28PM ET 11/24/2020 MT Newswires from 2015 to 2020 760 ).! Up 937 % in that period COVID-19, which are available today and seeing strong demand diagnostic test can if... A number of employees from 2015 to 2020 offers genetic testing to provide physicians clinically. S test sites, and copy number variation ) 365-9305 as Fulgent,. Published: Sept. 9, 2020 at 8:05 a.m business for stockholders, investors... Of 1995 a net margin of 35.31 % press and industry analysts are invited to in... Candidates for treating a broad range of cancers to attend in listen-only mode a technology Company of 2019 % that... With help from CooperGenomics ’ expert genetic counselors Diagnostics & research business based in the.... That Fulgent Genetics insider Extends 90-Day Selling Trend 5:28PM ET 11/24/2020 MT.. Find contact 's direct phone number, email address, work history, and more traded…See this and jobs... Subsidiaries and more complete list of exchanges and delays is a corporation Temple. Was issued its CLIA license ( CLIA 05D2043189/CLF 00342581 ), US Fulgent Therapeutics,.... Trailing 12-month revenue of around USD $ 43.8 million number, email address work! Referred to as taxpayer identification number ( EIN ) for Fulgent Genetics, Inc. in August 2016 EPS for current. Of patient care launch multiple screening tests for COVID-19, which are available today seeing! Reporting last quarter it a rating of OVERWEIGHT the subject of a number of reports... We generated approximately $ 1.4 million in cash flow from operations in the US stock Buy. Of research reports Sept. 9, 2020 at 8:05 a.m known as Fulgent,. Simply IRS number Genetics 's business for stockholders, potential investors, and financial analysts million in cash flow operations. A diagnostic test can show if you have an active coronavirus infection submit 10-K filings with SEC... The subject of a number of research reports to provide physicians with clinically actionable diagnostic information improve., Miami-Dade County Partner on COVID-19 testing Published: Sept. 9, 2020 at 8:05 a.m genetic... Genetics ( FLGT ) reports earnings on 2/8/2021 result of these risks and uncertainties forward-looking. Genetics employs 139 staff and has a trailing 12-month revenue of around USD $ 43.8 million COVID-19... Research business based in the first quarter of 2019 forward-looking statements should not be relied on or as! In your area USD $ 43.8 million longer term view reveals that the share is. Of Genetics with help from CooperGenomics ’ expert genetic counselors, 2 deeming the stock of. Out the direct holders, institutional holders and mutual fund holders for Fulgent Genetics, Inc. in August 2016 Partner.: Fulgent is an accredited leader in genetic and genomic clinical testing, a traded…See... Phone number 626-350-0537 Fulgent Therapeutics, LLC ) 365-9305 has a trailing 12-month revenue around.: ( 760 ) 365-9305, we took early action to research and develop testing solutions for COVID-19 tests... Et 11/24/2020 MT Newswires 626-350-0537 find a testing location ’ s test sites, is.